NDA 202331 · Azurity
Edarbyclor
Azilsartan Kamedoxomil, Chlorthalidone · Oral · Thiazide-like Diuretic
Last checked: Nov 20, 2026Latest source record: Mar 9, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Dec 20, 2011
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 0 recruiting
FAERS reports
1,259
648 serious, 39 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Edarbyclor as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue EDARBYCLOR as soon as possible ( 5.1 , 8.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.1 , 8.1 )
What it is approved for
From the label in effect Jul 1, 2022.
Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy. Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such as chlorthalidone and ARBs such as azilsartan medoxomil. There are no controlled trials demonstrating risk reduction with Edarbyclor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of...
Mechanism: The active ingredients of Edarbyclor target two separate mechanisms involved in blood pressure regulation. Azilsartan medoxomil Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzymes (ACE, kinase II). Angiotensin II is the principle pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Azilsartan medoxomil is an orally administered prodrug that is rapidly converted by esterases during absorption to the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 20, 2011 Original approval · Type 4 - New Combination Summary ReviewLabelReview
2 products under this application
- EDARBYCLOR · AZILSARTAN KAMEDOXOMIL EQ 40MG MEDOXOMIL; CHLORTHALIDONE 12.5MG · TABLET, ORAL · Prescription · TE AB
- EDARBYCLOR · AZILSARTAN KAMEDOXOMIL EQ 40MG MEDOXOMIL; CHLORTHALIDONE 25MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Azilsartan Kamedoxomil" as an intervention, any sponsor and status, largest first.
- Bioequivalence Study of Azilsartan Medoxomil 80 mg Tablets (Gedeon Richter Plc., Hungary) and Edarbi® 80 mg Tablets (JSC Nizhpharm, Russia)Not yet recruiting
Gedeon Richter Plc.Industry
NCT06990204 · 56 participants (planned) · Start Jun 6, 2025 · Primary completion Jul 1, 2025
Drug: Azilsartan medoxomil 80 mg tablet; Edarbi® 80 mg tablets · For: Hypertension
Sites: Perm, Russia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dizziness108
- fatigue78
- blood pressure increased72
- drug ineffective67
- diarrhoea62
- nausea62
- hypotension58
- hypertension56
- headache55
- asthenia49
- hyponatraemia47
- dyspnoea44
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 33 |
| 2013 | 31 |
| 2014 | 46 |
| 2015 | 68 |
| 2016 | 189 |
| 2017 | 144 |
| 2018 | 131 |
| 2019 | 133 |
| 2020 | 119 |
| 2021 | 76 |
| 2022 | 53 |
| 2023 | 80 |
| 2024 | 62 |
| 2025 | 60 |
| 2026 | 34 |
Recalls
2 FDA enforcement reports for this application.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Edarbyclor (Azilsartan Med/Chlorthalidone)
2024 spending
$26.2M
Beneficiaries
12,566
60,706 claims
Per beneficiary
$2,087
$7.85 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $25,688,267 |
| 2021 | $27,201,202 |
| 2022 | $27,376,602 |
| 2023 | $26,993,767 |
| 2024 | $26,222,487 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Single-pill Combination Therapy of Azilsartan Medoxomil/Chlorthalidone for Treatment of Hypertension: A Systematic Review.
Kwon A, Kim GH · Clin Ther 2020 · Systematic Review
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.